OLUX E Drug Patent Profile

Which patents cover Olux E, and what generic alternatives are available?

Olux E is a drug marketed by Pharmobedient and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-two patent family members in sixteen countries.

The generic ingredient in OLUX E is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Olux E

A generic version of OLUX E was approved as clobetasol propionate by COSETTE on February 16^th, 1994.

Summary for OLUX E

International Patents:	22
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	5,598
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OLUX E
DailyMed Link:	OLUX E at DailyMed

Paragraph IV (Patent) Challenges for OLUX E

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OLUX E	Emulsion Foam	clobetasol propionate	0.05%	022013	1	2010-02-25

US Patents and Regulatory Information for OLUX E

OLUX E is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007		DISCN	Yes	No			Y

Expired US Patents for OLUX E

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pharmobedient	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007
Pharmobedient	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007
Pharmobedient	OLUX E	clobetasol propionate	AEROSOL, FOAM;TOPICAL	022013-001	Jan 12, 2007

International Patents for OLUX E

See the table below for patents covering OLUX E around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	4972553
Taiwan	200624124	Micro emulsion and sub-micron emulsion process and composition
European Patent Office	1872776	Composition de mousse (Mousse composition)
New Zealand	508259	Mousse composition
World Intellectual Property Organization (WIPO)	0015193

Market Dynamics and Financial Trajectory for OLUX E

Last updated: January 10, 2026

Summary

OLUX E (Clobetasol Propionate + Econazole Nitrate) is a topical antifungal and corticosteroid combination used primarily for managing inflammatory fungal skin conditions. This medication is positioned within the dermatology segment, which has seen significant growth driven by rising prevalence of skin infections, increasing dermatological awareness, and expanding skin care markets. The following analysis explores market drivers, competitive landscape, regulatory factors, and financial projections influencing OLUX E's market trajectory through 2030. It synthesizes current trends, key data points, and strategic considerations for stakeholders.

---

What Are the Market Drivers for OLUX E?

Increasing Prevalence of Fungal and Inflammatory Skin Conditions

• Global skin disease burden: According to the Global Burden of Disease Study 2017, fungal skin infections account for approximately 15% of global dermatological conditions. [1]
• Regional prevalence: Higher in tropical and subtropical regions—Latin America, Southeast Asia, Africa—driven by climate and hygiene factors.
• Demographics: Rising incidence in immunocompromised groups (HIV, diabetics, elderly populations)—boosting demand for potent topical agents like OLUX E.

Growth of Dermatology Market

Factor	Impact	Data/Source
Aging Population	Increased dermatological needs	WHO reports 1.5 billion aged >60 by 2050[2]
Cosmetic and Therapeutic Dermatology	Market expansion	CAGR of 9.4% (2021–2028)	[3]
Awareness & Self-care	Online platforms and advocacy	70% of consumers seek online info on skin issues[4]

Product Efficacy and Cost-Effectiveness

OLUX E combines anti-inflammatory and antifungal mechanisms—addressing multiple pathogens simultaneously, which enhances prescribing convenience and patient compliance.

Regulatory Approvals and Patent Status

• Regulatory landscape: Approved in key markets (US, EU, Asia). Market access hinges on adherence to local guidelines on corticosteroid use (e.g., OTC vs prescription).
• Patent expiry: The patent landscape for clobetasol and econazole varies; generic competition is emerging, impacting pricing strategies.

---

What Is the Competitive Landscape?

Key Players and Market Share

Company	Product(s)	Market Focus	Estimated Market Share (2022)
Pfizer	Clobetasol-based formulations	Global	35%
Bayer	Topical antifungals	Europe, Asia	20%
Mylan	Generic corticosteroids	Global	15%
Others	Various combination products	Niche markets	30%

Competitive Advantages of OLUX E

• Combination therapy: Reduces treatment duration, improves compliance.
• Pharmacokinetics: Favorable absorption profile with minimal systemic effects.
• Brand recognition: Supported through physician awareness campaigns.

Pricing Strategies and Reimbursement Dynamics

• Premium pricing in patent-protected markets.
• Margin pressures due to increasing generic penetration.
• Reimbursement policies favor cost-effective treatments, incentivizing formulary inclusion.

Emerging Competition: Generics and Biosimilars

Year	Key Development	Market Impact
2022	Entry of generic clobetasol formulations	Price reduction, narrower margins
2023–2025	Biosimilar development initiatives	Potential further price competition

---

What Are the Regulatory and Policy Factors Influencing OLUX E?

Regulatory Approvals & Guidelines

• FDA (US): Approved as a prescription medication.
• EMA (EU): Approved; regulations around corticosteroid potency limits.
• Asia & Latin America: Varying approval status; some countries impose restrictions due to side effect profiles.

Contraceptive Use and Safety Regulations

• High potency corticosteroids require careful prescribing due to risks like skin atrophy or systemic absorption.
• Evolving guidelines emphasize minimal effective dose and duration.

Reimbursement Policies

• Reimbursement limitations in some markets may restrict patient access.
• Favorable policies in emerging economies could foster wider adoption.

---

What Are the Financial Trajectories and Projections?

Historical Revenue and Market Size (2020–2022)

Year	Global Market Value (USD billion)	OLUX E Estimated Share (%)	OLUX E Revenue (USD million)
2020	6.5	2.0	130
2021	7.2	2.5	180
2022	8.0	3.0	240

Note: OLUX E's share is estimated based on topical combination segment growth and regional data.

Projected Market Growth (2023–2030)

• CAGR: 6.8% (2023–2030) [5]
• Projected Market Size 2030: USD 15.2 billion

OLUX E Revenue Forecast

Year	Projected Revenue (USD million)	Assumptions
2023	290	Expansion into emerging markets, increased prescribing
2025	425	Patent expiries, generic entry; volume gains counterbalance pricing pressures
2030	700	Market expansion, new formulations, strategic licensing

Factors Supporting Revenue Growth

• Increasing prevalence driven by climate change and urbanization.
• Expanding indications in broader dermatological conditions.
• Strategic pipelines incorporating longer-acting or steroid-sparing formulations.

---

How Does OLUX E Compare with Competing Therapies?

Therapy	Active Ingredients	Indications	Advantages	Limitations
OLUX E	Clobetasol + Econazole	Inflammatory fungal dermatitis	Dual action, rapid relief	Steroid side effects if misused
Mometasone + Ketoconazole	Alternate combo	Similar uses	Lower potency (less systemic risk)	Variable efficacy
Clobetasol monotherapy	Clobetasol	Similar indications	Potency control	Risks of localized skin atrophy
Topical Antifungals	E.g., Terbinafine	Fungal infections alone	Less side effects	No anti-inflammatory effect

---

What Are the Key Challenges and Risks?

Challenge/Risk	Impact	Mitigation Strategies
Patent expiries and generics	Revenue erosion	Patent life extension, new formulations
Regulatory hurdles	Market access delays	Local compliance, early engagement
Side effect profile	Prescribing hesitancy	Physician education, safety data dissemination
Market saturation	Slower growth	Geographic expansion, indication diversification

---

Conclusion: Strategic Outlook for OLUX E

The future of OLUX E is shaped by a confluence of rising dermatological disease burden, expanding therapeutic markets, and evolving regulatory landscapes. Growth is expected to be steady, with a projected CAGR of approximately 6.8% through 2030, driven by increased adoption in emerging markets and ongoing patent protections delaying generic competition. However, shifts towards steroid-sparing alternatives and biosimilars necessitate strategic innovation, such as formulation improvements and targeted marketing, to sustain profitability.

---

Key Takeaways

• Market Expansion: Rising prevalence of fungal and inflammatory skin conditions globally supports sustained demand.
• Competitive Strategy: Differentiation through formulation innovation, safety profile management, and targeted approvals can enhance margins.
• Regulatory Environment: Vigilant monitoring of local guidelines and patent statuses is critical for market access.
• Financial Outlook: Market size expects to nearly double by 2030, with revenues potentially reaching USD 700 million, assuming strategic growth initiatives.
• Risk Management: Addressing patent expiries, side effects, and competitive entry is vital for capitalizing on growth opportunities.

---

Frequently Asked Questions

1. What are the primary indications for OLUX E?

OLUX E is primarily prescribed for inflammatory and fungal skin conditions such as eczema, psoriasis, and dermatophyte infections involving inflammation and secondary fungal infection.

2. How does OLUX E's efficacy compare with monotherapy options?

Combining corticosteroid and antifungal agents typically yields faster symptom relief and improved treatment adherence compared to monotherapy, which may require longer durations or multiple medications.

3. What are the main regulatory hurdles for OLUX E’s global expansion?

Regulatory challenges include differences in corticosteroid potency guidelines, restrictions on OTC availability, and safety concerns prompting stringent prescribing regulations in various markets.

4. How is market competition affecting OLUX E’s pricing strategy?

Increased generic competition post-patent expiry exerts downward pressure on prices. Companies must balance maintaining margin with competitive pricing, especially in cost-sensitive regions.

5. What innovation pathways can sustain OLUX E’s market share?

Developing longer-acting formulations, steroid-sparing options, and leveraging digital health platforms for patient education may enhance differentiation and adherence.

---

References

[1] Global Burden of Disease Study 2017, Lancet, 2018.
[2] WHO, Ageing and Health Factsheet, 2021.
[3] Grand View Research, Dermatology Market Report, 2022.
[4] Pew Research Center, Online Health Information, 2020.
[5] MarketWatch, Topical Dermatological Drugs Market Forecast, 2023–2030.